EP3349768A4 - ANTIBODIES FOR THE PRODUCTION OF ANTI-INFLAMMATORY MACROPHAGES AND USES THEREOF - Google Patents

ANTIBODIES FOR THE PRODUCTION OF ANTI-INFLAMMATORY MACROPHAGES AND USES THEREOF Download PDF

Info

Publication number: EP3349768A4
Authority: EP; European Patent Office
Prior art keywords: antibodies; production; inflammatory macrophages; macrophages; inflammatory
Prior art date: 2015-09-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP16847105.0A

Other languages

German (de)

French (fr)

Other versions

EP3349768A1 (en

Inventor

Kyung Ho Han

Richard A. Lerner

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Scripps Research Institute

Original Assignee

Scripps Research Institute

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-09-15

Filing date

2016-09-12

Publication date

2019-01-23

2016-09-12 Application filed by Scripps Research Institute filed Critical Scripps Research Institute

2018-07-25 Publication of EP3349768A1 publication Critical patent/EP3349768A1/en

2019-01-23 Publication of EP3349768A4 publication Critical patent/EP3349768A4/en

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/17—Monocytes; Macrophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Hematology (AREA)
General Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Transplantation (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

EP16847105.0A 2015-09-15 2016-09-12 ANTIBODIES FOR THE PRODUCTION OF ANTI-INFLAMMATORY MACROPHAGES AND USES THEREOF Withdrawn EP3349768A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562218785P	2015-09-15	2015-09-15
PCT/US2016/051290 WO2017048629A1 (en)	2015-09-15	2016-09-12	Antibodies for generating anti-inflammatory macrophage and related uses

Publications (2)

Publication Number	Publication Date
EP3349768A1 EP3349768A1 (en)	2018-07-25
EP3349768A4 true EP3349768A4 (en)	2019-01-23

Family

ID=58289788

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP16847105.0A Withdrawn EP3349768A4 (en)	2015-09-15	2016-09-12	ANTIBODIES FOR THE PRODUCTION OF ANTI-INFLAMMATORY MACROPHAGES AND USES THEREOF

Country Status (3)

Country	Link
EP (1)	EP3349768A4 (en)
AU (1)	AU2016324021A1 (en)
WO (1)	WO2017048629A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2023146860A1 (en) *	2022-01-28	2023-08-03	The George Washington University	Compositions for and methods of treating a subject having inflammation
CN116445407B (en) *	2023-06-16	2023-09-08	广州正源生物技术有限公司	Extraction and amplification culture method of placenta macrophages

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060272041A1 (en) *	2001-09-24	2006-11-30	Wisotzkey Robert G	Cathepsin G (CTSG) Disruptions, Compositions and Methods Relating Thereto
US7786269B2 (en) *	2001-12-04	2010-08-31	Dana-Farber Cancer Institute, Inc.	Antibody to latent membrane proteins and uses thereof
UA106771C2 (en) *	2009-10-16	2014-10-10	Ле Лаборатуар Сервьє	Monoclonal antibodies to progastrin and their application
US20130142760A1 (en) *	2010-08-18	2013-06-06	Cedars-Sinai Medical Center	Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer
EP2708560A4 (en) *	2011-05-09	2015-01-14	Perseus Proteomics Inc	ANTIBODIES SPECIFICALLY RECEIVING A TRANSFERRIN RECEPTOR

2016
- 2016-09-12 WO PCT/US2016/051290 patent/WO2017048629A1/en not_active Ceased
- 2016-09-12 EP EP16847105.0A patent/EP3349768A4/en not_active Withdrawn
- 2016-09-12 AU AU2016324021A patent/AU2016324021A1/en not_active Abandoned

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
B. KORKMAZ ET AL: "Neutrophil Elastase, Proteinase 3, and Cathepsin G as Therapeutic Targets in Human Diseases", PHARMACOLOGICAL REVIEWS, vol. 62, no. 4, 15 November 2010 (2010-11-15), US, pages 726 - 759, XP055535637, ISSN: 0031-6997, DOI: 10.1124/pr.110.002733 *
DAVID G LOMAS ET AL: "The Control of Neutrophil Chemotaxis by Inhibitors of", J. BIOL. CHEM., 1 January 1995 (1995-01-01), pages 23437 - 23443, XP055535631, Retrieved from the Internet <URL:http://www.jbc.org/content/270/40/23437.full.pdf> [retrieved on 20181217] *
KEITH M SKUBITZ ET AL: "Preparation and Characterization of Monoclonal Antibodies to Human Neutrophil Cathepsin G, Lactoferrin, Eosinophil Peroxidase, and Eosinophil Major Basic Protein", JOURNAL OF LEUKOCYTE BIOLOGY, 1 January 1989 (1989-01-01), pages 109 - 118, XP055535628, Retrieved from the Internet <URL:https://jlb.onlinelibrary.wiley.com/doi/pdf/10.1002/jlb.46.2.109> [retrieved on 20181217] *
NADINE JETTEN ET AL: "Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo", ANGIOGENESIS, vol. 17, no. 1, 8 September 2013 (2013-09-08), NL, pages 109 - 118, XP055535574, ISSN: 0969-6970, DOI: 10.1007/s10456-013-9381-6 *
NAUDER FARADAY ET AL: "Cathepsin G-Dependent Modulation of Platelet Thrombus Formation In Vivo by Blood Neutrophils", PLOS ONE, vol. 8, no. 8, 5 August 2013 (2013-08-05), pages e71447, XP055535633, DOI: 10.1371/journal.pone.0071447 *
PAOLO CONROTTO ET AL: "Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comnparative mass spectrometry analysis", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 123, no. 12, 15 December 2008 (2008-12-15), pages 2856 - 2864, XP002663352, ISSN: 0020-7136, [retrieved on 20080916], DOI: 10.1002/IJC.23861 *
RICHARD A. LERNER ET AL: "Antibodies from combinatorial libraries use functional receptor pleiotropism to regulate cell fates", QUARTERLY REVIEWS OF BIOPHYSICS., vol. 48, no. 04, 16 July 2015 (2015-07-16), pages 389 - 394, XP055238228, ISSN: 0033-5835, DOI: 10.1017/S0033583515000049 *
See also references of WO2017048629A1 *

Also Published As

Publication number	Publication date
EP3349768A1 (en)	2018-07-25
AU2016324021A1 (en)	2018-04-12
WO2017048629A1 (en)	2017-03-23

Publication	Publication Date	Title
MA47694A (en)	2021-05-19	ANTI-TIGIT ANTIBODY
MA49034A (en)	2020-02-12	ANTI-LAG3 ANTIBODY
MA47268A (en)	2019-11-20	ANTIBODY ANTI-GPC3
MA45231A (en)	2021-05-05	ANTI-BODY ANTI-IGE
EP3423089A4 (en)	2019-10-23	ANTI-TIGIT ANTIBODIES
MA53297A (en)	2022-05-04	ANTI-ICOS ANTIBODIES
EP3334757A4 (en)	2019-04-03	ANTI-TIGIT ANTIBODIES
EP3297671A4 (en)	2019-02-06	ANTI-ROR1 ANTIBODIES
MA49537A (en)	2020-05-13	ANTI-LAG3 ANTIBODIES AND THEIR USES
EP3294865A4 (en)	2019-06-26	PROCESSES FOR THE PRODUCTION OF EPIMERASES AND ALKALOIDS BENZYLISOQUINOLINE
EP3283516A4 (en)	2019-03-06	ANTI-PACAP ANTIBODIES AND USES THEREOF
MA44236A (en)	2018-12-26	ANTI-TGFBETA ANTIBODY 2
MA43660A (en)	2018-11-28	ANTI-COAGULATION FACTOR XI ANTIBODY
MA45233A (en)	2019-04-17	ANTI-GITR ANTIBODIES AND THEIR USES
EP3526247A4 (en)	2021-04-14	ANTI-IL1-RAP ANTIBODIES
EP3399992A4 (en)	2019-07-31	AUTORESTICULANT ANTIBODIES
EP3617231A4 (en)	2021-04-07	ANTI-GPC-1 ANTIBODY
MA45234A (en)	2019-04-17	ANTI-COAGULATION FACTOR XI ANTIBODY
EP3349794A4 (en)	2019-07-31	ANTI-CD115 ANTIBODIES
MA51134A (en)	2021-03-24	ANTI-ALPHA-SYNUCLEIN ANTIBODY
EP3381941A4 (en)	2019-05-01	ANTI-EPHA4 ANTIBODIES
EP3336185A4 (en)	2019-01-16	ANTIBODY
MA51135A (en)	2021-03-24	ANTI-ALPHA-SYNUCLEIN ANTIBODY
MA50654A (en)	2020-08-05	ANTI-PACAP ANTIBODIES
MA49257A (en)	2020-04-15	ANTI-TRKB ANTIBODIES

Legal Events

Date	Code	Title	Description
2018-06-22	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2018-07-25	17P	Request for examination filed	Effective date: 20180326
2018-07-25	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2018-07-25	AX	Request for extension of the european patent	Extension state: BA ME
2018-12-19	DAV	Request for validation of the european patent (deleted)
2018-12-19	DAX	Request for extension of the european patent (deleted)
2019-01-23	A4	Supplementary search report drawn up and despatched	Effective date: 20190104
2019-01-23	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 35/12 20150101ALI20181220BHEP Ipc: C12N 5/0786 20100101ALI20181220BHEP Ipc: C07K 16/40 20060101AFI20181220BHEP Ipc: A61K 49/16 20060101ALI20181220BHEP Ipc: A61K 35/15 20150101ALI20181220BHEP
2020-01-10	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2020-02-12	18D	Application deemed to be withdrawn	Effective date: 20190802